CONTENTS
· Scientific Agenda
· Invitation
· Continuing Medical Education
· Who Should Attend?
· Objectives
· Registration
· General Information
· Hotel Accommodations
· Organizer

Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Bart Barlogie, MD, PhD
Myeloma Institute
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Nancy L. Bartlett, MD
Washington University
School of Medicine
St. Louis, Missouri

James R. Berenson, MD
Institute for Myeloma and Bone Cancer Research
West Hollywood, California

George P. Canellos, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Selina Chen-Kiang, PhD
Department of Pathology
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Nicholas Chiorazzi, MD
North Shore-Long Island Jewish Research Institute
Manhasset, New York

Hearn J. Cho, MD, PhD
New York University Cancer Institute
New York, New York

Bertrand Coiffier, MD
University Hospital
Lyon, France

Morton Coleman, MD
Chair
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Myron S. Czuczman, MD
Roswell Park Cancer Institute
Buffalo, New York

Volker Diehl, MD, PhD
University of Cologne
Cologne, Germany

Brian G.M. Durie, MD
Cedars-Sinai Comprehensive
Cancer Center
Los Angeles, California

Joshua Epstein, DSc
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Richard I. Fisher, MD
University of Rochester Medical Center
Rochester, New York

Rafael Fonseca, MD
Mayo Clinic Scottsdale
Scottsdale, Arizona

Francine M. Foss, MD
Yale Cancer Center
New Haven, Connecticut

Richard R. Furman, MD
Co-Chair, Leukemia Session
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Randy D. Gascoyne, MD
British Columbia Cancer Center
Vancouver, British Columbia, Canada

Morie A. Gertz, MD
Mayo Clinic
Rochester, Minnesota

Andre P. Goy, MD
Hackensack University
Medical Center
Hackensack, New Jersey

Jean-Luc Harousseau, MD
University of Nantes
Nantes, France

Sandra J. Horning, MD
Stanford University
Medical Center
Stanford, California

Sundar Jagannath, MD
St. Vincent's Comprehensive
Cancer Center
New York, New York

David K. Jin, MD
Center for Lymphoma and Myeloma
New York Medical Center
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Neil E. Kay, MD
Mayo Clinic
Rochester, Minnesota

Lale Kostakoglu, MD
Mt. Sinai Medical Center
New York, New York

Robert A. Kyle, MD, PhD
Mayo Clinic
Rochester, Minnesota

Joseph M. Lane, MD
Weill Medical College, Hospital for Special Surgery
New York, New York

Norman Latov, MD, PhD
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

John P. Leonard, MD
Co-Chair, Lymphoma Session
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Ronald Levy, MD
Stanford University
School of Medicine
Stanford, California

Andrew Lister, MD, FRCP,
FRCPath, FRCR
Queen Mary’s School of Medicine
London, United Kingdom

David G. Maloney, MD
Fred Hutchinson Cancer
Research Center
Seattle, Washington

Thomas P. Miller, MD
Arizona Cancer Center
Tucson, Arizona

Nikhil Munshi, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Gwen L. Nichols, MD
Columbia University College of Physicians and Surgeons
The New York Presbyterian Hospitals
New York, New York

Ruben Niesvizky, MD
Co-Chair, Myeloma Session
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Owen A. O’Connor, MD, PhD
Memorial Sloan-Kettering
Cancer Center
Weill Medical College of Cornell University
New York, New York

Roger N. Pearse, MD, PhD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Michael Pfreundschuh, MD
Saarland University
Homburg, Germany

Paul G. Richardson, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

G. David Roodman, MD, PhD
VA Pittsburgh Healthcare System
Pittsburgh, Pennsylvania

Jesus F. San Miguel, MD
University Hospital of Salamanca
Salamanca, Spain

Michael W. Schuster, MD
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

John D. Shaughnessy Jr., PhD
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Tsiporah B. Shore, MD
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

David S. Siegel, MD, PhD
Hackensack University
Medical Center
Hackensack, New Jersey

David J. Straus, MD
Memorial Sloan-Kettering
Cancer Center
Weill Medical College of Cornell University
New York, New York

Steven P. Treon, MD, PhD
Dana-Farber Cancer Institute
Harvard School of Medicine
Boston, Massachusetts

Julie M. Vose, MD
University of Nebraska
Medical Center
Omaha, Nebraska

Mark A. Weiss, MD
Memorial Sloan-Kettering
Cancer Center
Weill Medical College of Cornell University
New York, New York

Anas Younes, MD
MD Anderson Cancer Center
Houston, Texas

Maurizio Zangari, MD
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Pier Luigi Zinzani, MD
University of Bologna
Bologna, Italy

Thursday, October 19
8:30 am
Welcome and introduction
Morton Coleman, MD

Myeloma Section
8:35 am
Introduction
Ruben Niesvizky, MD

Session I: The Biology of Myeloma
Chair: Ruben Niesvizky, MD
8:40 am
Chair introduction

8:45 am
Cytogenetics, FISH and beyond
Rafael Fonseca, MD

9:05 am
Genomic characterizations: Opportunity for new targets
John D. Shaughnessy Jr., PhD

9:25 am
Animal models and imaging
Joshua Epstein, DSc

9:45 am
Angiogenesis: VEGF and beyond
David K. Jin, MD

10:05 am
Cell cycle control in myeloma
Selina Chen-Kiang, PhD

10:25 am
Panel discussion

10:40 am
Special Award Ceremony
Joseph Michaeli Award for contributions to Myeloma
Recipient: Robert A. Kyle, MD, PhD

10:50 am
Break

Session II: Bone Disease
Chair: Roger N. Pearse, MD, PhD
11:10 am
Chair introduction

11:15 am
Pathogenesis of bone disease
G. David Roodman, MD, PhD

11:35 am
Treatment of bone disease
James R. Berenson, MD

11:55 am
Kyphoplasty
Joseph M. Lane, MD

12:10 pm
Panel discussion

Session III: Treatment I
Chair: Morton Coleman, MD
2:00 pm
Chair introduction

2:05 pm
Recent advances in diagnosis and staging: Free light chain assays and PET/CT
Brian G. M. Durie, MD

2:25 pm
MGUS and smoldering myeloma
Morie A. Gertz, MD

2:45 pm
Thrombosis in myeloma
Maurizio Zangari, MD

3:05 pm
Panel discussion

3:15 pm
Break

Session IV: Treatment II
Chair: Sundar Jagannath, MD
3:40 pm
Chair introduction

3:45 pm
How to treat relapsed, refractory myeloma?
Morton Coleman, MD

4:05 pm
Opinion – Should bortezomib or lenalidomide be considered initial therapy for myeloma?
Paul G. Richardson, MD and Ruben Niesvizky, MD

4:25 pm
Toward a new paradigm in the treatment of multiple myeloma
Kenneth C. Anderson, MD

4:45 pm
Panel discussion

5:00 pm
Adjourn

Friday, October 20, 2006

Session V: High Dose Chemotherapy and Transplantation
Chair: Tsiporah B. Shore, MD
8:00 am
Chair introduction

8:05 am
Debate – To transplant or not to transplant:
When to transplant
Jesus F. San Miguel, MD and Jean-Luc Harousseau, MD

8:35 am
Lessons of total therapy
Bart Barlogie, MD, PhD

9:00 am
Panel discussion

Session VI: Waldenstrom’s Macroglobulinemia
Chair: Robert A. Kyle, MD, PhD
9:15 am
Chair introduction

9:20 am
Approach to neuropathy in WM
Norman Latov, MD, PhD

9:40 am
What should be considered standard initial therapy for WM?
Gwen L. Nichols, MD

10:00 am
New approaches for the treatment of WM
Steve P. Treon, MD, PhD

10:20 am
Panel discussion

10:35 am
Break

Session VII: Chronic Lymphocytic Leukemia
Chair: Mark A. Weiss, MD
11:00 am
Chair introduction

11:05 am
How should we use prognostic factors to guide treatment in CLL?
Richard R. Furman, MD

11:25 am
Standard therapy for CLL
Mark A. Weiss, MD

11:45 am
New agents for the treatment of CLL
Neil E. Kay, MD

12:05 pm
Why is CLL such a heterogeneous disease?
Nicholas Chiorazzi, MD

12:25 pm
Panel discussion

Session VIII: Immunotherapy Update
Chair: David S. Siegel, MD, PhD
2:00 pm
Chair introduction

2:05 pm
Immunologic considerations in myeloma and the role of vaccines
Nikhil Munshi, MD

2:25 pm
Vaccine immunotherapy targeting type I MAGE in multiple myeloma
Hearn Cho, MD, PhD

2:45 pm
Immunotherapy in B cell malignancies: Past and future perspectives
Ronald Levy, MD

3:10 pm
Panel discussion

3:25 pm
Break

Lymphoma Section

3:50 pm
Introduction
John P. Leonard, MD

Session IX: Hodgkin’s Disease
Chair: David J. Straus, MD
3:55 pm
Chair introduction

4:00 pm
Optimal management: New approaches for disseminated Hodgkin’s
Nancy L. Bartlett, MD

4:20 pm
Optimal management of limited stage Hodgkin’s disease: Is there a role for radiation?
George P. Canellos, MD

4:40 pm
Risk and response based innovative studies for advanced Hodgkin’s lymphoma
Volker Diehl, MD, PhD

5:00 pm
Panel discussion

5:15 pm
Adjourn

Saturday, October 21, 2006

Session X: Aggressive Lymphomas
Chair: Morton Coleman, MD
8:00 am
Chair introduction

8:05 am
Clinical overview of T cell lymphoma
Julie M. Vose, MD

8:25 am
Approach to CTCL
Francine M. Foss, MD

8:45 am
Clinical translation of gene expression profiling in diffuse large B cell lymphoma
Randy D. Gascoyne, MD

9:05 am
Sorting out the heterogeneity of DLBCL
Randy D. Gascoyne, MD

9:25 am
Primary mediastinal DLBCL: Is it a different disease?
Pier Luigi Zinzani, MD

9:45 am
Panel discussion

10:00 am
Special Award Ceremony
John Ultmann Award for contributions to Lymphoma
Recipient: Ronald Levy, MD

10:10 am
Break

Session XI: Large Cell Lymphoma
Chair: Michael W. Schuster, MD
10:35 am
Chair introduction

10:40 am
Approach to early stage DLBCL
Thomas P. Miller, MD

11:00 am
Approach to advanced stage DLBCL
Michael Pfreundschuh, MD

11:20 am
Approach to relapsed DLBCL?
Richard I. Fisher, MD

11:40 am
Panel discussion

Session XII: Indolent Lymphomas
Chair: John P. Leonard, MD
1:15 pm
Chair introduction

1:20 pm
Initial management of follicular NHL
Sandra J. Horning, MD

1:40 pm
Should every patient with indolent lymphoma receive maintenance anti-CD20 antibody therapy?
David G. Maloney, MD

2:00 pm
Role of radioimmunotherapy in management of NHL
John P. Leonard, MD

2:20 pm
New approaches to monoclonal antibody therapy
Myron S. Czuczman, MD

2:40 pm
Approach to marginal zone lymphoma
Bertrand Coiffier, MD

3:00 pm
Diagnosis, prognosis and treatment of transformed lymphoma
Andrew Lister, MD

3:20 pm
Panel discussion

Session XIII: New Approaches
Chair: Richard R. Furman, MD
3:35 pm
Chair introduction

3:40 pm
Novel immunotherapies for treatment of lymphoma
Anas Younes, MD

4:00 pm
Novel cytotoxics and small molecules for treatment of lymphoma
Owen A. O’Connor, MD, PhD

4:20 pm
New approaches to mantle cell lymphoma
Andre P. Goy, MD

4:40 pm
PET scanning in lymphoma and myeloma: A new paradigm for treatment
Lale Kostakoglu, MD

5:00 pm
Panel discussion

5:10 pm
Closing remarks & adjourn

On behalf of the Center for Lymphoma and Myeloma at Weill Medical College of Cornell University, I would like to invite you to attend the Fourth Lymphoma & Myeloma Conference to be held on October 19-21, 2006 at the Waldorf=Astoria Hotel in New York City. Since 2000, this conference has provided a broad update and overview of the rapidly expanding knowledge in lymphoma and myeloma. In 2004, over 500 people attended the conference and this popularity allows us to mark 2006 as the first year of the conference moving to an annual schedule.
 
Lymphoma & Myeloma will draw on the expertise of more than 50 leaders in the fields of molecular biology, pathology, immunology, translational and clinical research. We plan to provide an integrated format so that the attendees will have a thorough understanding of the evolution of thought and therapy of the topics under discussion. This integrated, interdisciplinary approach should make for a stimulating, interactive setting for all members of the medical and scientific community interested in lymphocyte development, trafficking, pathology and treatment.

October is a particularly delightful time to be in New York and, as always, this capital city of the world is as exciting as ever. We cordially welcome you to our fair city and hope to reward you with an exciting, informative conference.
 
Sincerely,
Morton Coleman, MD, Chair

Imedex^®, Inc.is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This conference is designated for a maximum of 20.0 Category 1 credit hours towards the AMA Physician’s Recognition Award. Participants should only claim those hours that he/she spent in the activity.

*Information on CME accreditation for each of the luncheon symposia may be found in the individual symposium materials.

After successfully completing this continuing medical education program participants should be able to:

• Outline the basic biology of myeloma, lymphoma, and related plasma cell disorders
• Summarize the most important genetic and molecular abnormalities of myeloma and lymphoma cells
• Describe the processes of bone disease in myeloma and novel treatment strategies
• Implement the most clinically effective management strategies for the various types and stages of lymphoma, myeloma and related disorders
• Identify promising new drugs and therapy combinations for the treatment of myeloma and lymphoma
• Comment on the emerging role of vaccines in lymphoma and myeloma

Click here to register for this program

Registration Fees for Physicians
Regular: $ 445 (f payment received by October 11, 2006)
On-site: $ 545(If payment received after October 11, 2006)

Registration Fees for Pharmacists*
Regular: $ 295 (If payment received by October 11, 2006)
On-site: $ 345 (If payment received after October 11, 2006)

Nurses/Residents/Students* $ 99
*Proof of eligibility must accompany registration

Registration Fees
To Register: You may register online or by calling Imedex at +1 (770) 751 7332 Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment: Registration fees and hotel reservation guarantees can be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add $25 to the registration fee to cover bank charges. Include the full name of the attendee and the name of the conference: 242 Lymphoma & Myeloma 2006. Attendee is not registered until full payment is received.

Wire to: Bank of America, ABA: 0260.0959.3, Account Info: Imedex, Inc., Account: 0000.0106.3308. If the wire originates outside the United States, please add this additional information: Clearing Bank: Bank of America, New York, Swift Code: BOFAUS3N, Clearing Account: 6550305831. Wire payments must be received by Imedex by October 12, 2006.

Registration Fee Inclusions: Registration fees include admittance to scientific sessions, conference materials and all functions as specified in the program.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at Imedex by October 12, 2006. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. After October 12, 2006, no refunds will be made.

For hotel deposits to be refunded, written notice of cancellation must be received at Imedex no later than 5 business days prior to your scheduled arrival date. All refunds will be processed after the conference.

Imedex does not accept responsibility for covering travel, accommodations or any other costs incurred by registrants in the rare event that this program should be cancelled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event program content is subject to change without notice.

Conference Location
The Waldorf=Astoria
301 Park Avenue
New York, New York 10022
Tel.: +1 (800) 925 3673
Fax: +1 (212) 872 7272

DISCOUNTED AIRFARES
Contact conference travel agent, Age of Travel, for assistance with your travel needs. Age of Travel can also accommodate pre- and post-
conference extensions.
Tel.: +1 (800) 523 4954 or Tel.: +1 (404) 591 7120
Email: Imedex@ageoftravel.com

          4325 Alexander Drive
          Alpharetta, GA 30022-3740 USA
          Tel.: +1 (770) 751 7332
          Fax: +1 (770) 751 7334
          Email: meetings@imedex.com
          Web: www.imedex.com